Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue, net	$ 11,155	$ 5,446	$ 20,989	$ 14,504
Cost of revenue (excluding amortization of $1,112 and $1,115 for the three months and $2,224 and $2,230 for the six months, respectively)	5,800	3,850	11,116	9,963
Gross profit	5,355	1,596	9,873	4,541
Operating expenses:
Sales and marketing	2,776	1,596	5,128	4,077
Research and development	424	550	1,060	1,360
General and administrative	3,326	3,983	6,305	8,819
Transition expenses	858	124	2,111	180
Gain on DiamiR transaction	(235)		(235)
Acquisition related amortization expense	1,112	1,115	2,224	2,230
Total operating expenses	8,261	7,368	16,593	16,666
Operating loss	(2,906)	(5,772)	(6,720)	(12,125)
Interest accretion expense	(135)	(167)	(270)	(276)
Other (expense) income , net	(331)	438	(520)	485
Loss from continuing operations before tax	(3,372)	(5,501)	(7,510)	(11,916)
Provision for income taxes	16	13	31	28
Loss from continuing operations	(3,388)	(5,514)	(7,541)	(11,944)
Loss from discontinued operations, net of tax	(58)	(66)	(112)	(130)
Net loss	(3,446)	(5,580)	(7,653)	(12,074)
Less adjustment for preferred stock deemed dividend				(3,033)
Net loss attributable to common stockholders	$ (3,446)	$ (5,580)	$ (7,653)	$ (15,107)
Basic and diluted loss per share of common stock:
From continuing operations	$ (0.83)	$ (1.37)	$ (1.84)	$ (3.73)
From discontinued operations	(0.01)	(0.01)	(0.03)	(0.03)
Net loss per basic and diluted share of common stock	$ (0.84)	$ (1.38)	$ (1.87)	$ (3.76)
Weighted average number of common shares and common share equivalents outstanding:
Basic	4,102	4,033	4,095	4,018
Diluted	4,102	4,033	4,095	4,018